Target intelligence / Profile preview

Long intergenic non-protein coding RNA 1419 (LINC01419)

Target: LINC01419
Molecular classification: Long non-coding RNA (lncRNA), Epigenetic regulator (by interaction with EZH2[4]), Other

Overview

Long intergenic non-protein coding RNA 1419 (LINC01419) is a long non-coding RNA implicated in cancer biology. It acts as an oncogene in hepatocellular carcinoma, esophageal squamous cell carcinoma, and osteosarcoma, promoting cell proliferation, migration, and survival, mainly by modulating DNA damage repair pathways and epigenetic gene regulation. LINC01419 binds XRCC5/Ku80 to promote genome stability and suppresses apoptosis; it can regulate gene methylation through interaction with epigenetic modulators (EZH2, GSTP1). Overexpression correlates with poor prognosis and increased chemoresistance in multiple cancers, making it an attractive candidate for biomarker development and targeted therapy[1][2][3][4][5].

Other names: TCONS_00014497PRLH1 (p53-regulated lncRNA for homologous recombination repair 1)LVCAT7Liver cancer-associated transcript 7p53-regulated lncRNA for homologous recombination (HR) repair 1

Mechanism of action

Knockdown or inhibition leads to decreased cell proliferation, increased apoptosis, increased DNA damage, and tumor growth suppression[1][2][3]. Epigenetic drugs or agents affecting DNA repair may leverage LINC01419-associated pathways to increase sensitivity to chemotherapy[3].

Biological functions

Cell proliferation[1][2][4]Cell migration and motility[1][2][4]Epithelial-mesenchymal transition (EMT)[1]DNA damage repair (regulation through XRCC5/Ku80, homologous recombination, genomic stability)[2][3][4]Epigenetic regulation (histone methylation via EZH2 binding, promoter methylation of target genes like RECK and GSTP1)[3][4]Chemoresistance (modifying sensitivity to agents like doxorubicin and 5-fluorouracil)[2][3]

Disease associations

Cancer (Hepatocellular carcinoma, Esophageal squamous cell carcinoma, Osteosarcoma)[1][2][3][4][5]Other: Strong links to tumorigenesis and poor prognosis in various malignancies

Safety considerations

No established safety concerns for direct targeting, but as LINC01419 is involved in genomic stability and DNA repair, its inhibition could potentially increase off-target genomic instability or sensitize normal tissue to DNA damage. These risks should be evaluated during therapeutic development[2].

Interacting drugs

Doxorubicin (chemoresistance modulated by LINC01419 in HCC)[2]

3 more in the full profile.

Biomarkers

Elevated expression of LINC01419 (diagnostic/prognostic biomarker in HCC and ESCC)[2][3][4]GSTP1 methylation status (related to LINC01419 activity in ESCC)[3]XRCC5/Ku80 phosphorylation (indirectly influenced by LINC01419, linked to DNA repair status)[2]

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 1419 (LINC01419).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 1419 (LINC01419).

Explore the full profile